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Background: Blood-based biomarkers have been proposed as an alternative to current
sputum-based treatment monitoring methods in active tuberculosis (ATB). The aim of
this study was to validate previously described phenotypic, activation, and cytokine
markers of treatment response in a West African cohort.
Methods: Whole blood immune responses to Mycobacterium tuberculosis ESAT-
6/CFP-10 (EC) and purified protein derivative (PPD) were measured in twenty adults
at baseline and after 2 months of standard TB treatment. Patients were classified
as fast or slow responders based on a negative or positive sputum culture result
at 2 months, respectively. Cellular expression of activation markers (CD38, HLA-DR),
memory markers (CD27), and functional intracellular cytokine and proliferation (IFN-γ,
Ki-67, TNF-α) markers were measured using multi-color flow cytometry.
Results: There was a significant increase in the proportion of CD4+CD27+ cells
expressing CD38 and HLA-DR following EC stimulation at 2 months compared to
baseline (p = 0.0328 and p = 0.0400, respectively). Following PPD stimulation,
slow treatment responders had a significantly higher proportion of CD8+CD27−IFN-
γ
+ (p = 0.0105) and CD4+CD27+HLA-DR+CD38+ (p = 0.0077) T cells than fast
responders at baseline. Receiver operating curve analysis of these subsets resulted
in 80% sensitivity and 70 and 100% specificity, respectively (AUC of 0.82, p = 0.0156
and 0.84, p = 0.0102).
Conclusion: Our pilot data show reductions in expression of T cell activation markers
were seen with treatment, but this was not associated with fast or slow sputum
conversion at 2 months. However, baseline proportions of activated T cell subsets are
potentially predictive of the subsequent speed of response to treatment.
Keywords: tuberculosis, treatment, activation markers, cytokines, immunity
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INTRODUCTION
The World Health Organization’s (WHO) 2018 Global
Tuberculosis (TB) report estimated that 10 million people
developed active TB (ATB) disease in 2018 resulting in 1.6
million deaths (1). One hurdle inhibiting control over the
TB epidemic is the challenge of accurately monitoring and
predicting treatment responses in a timely, efficient, reliable,
and cost-effective manner. Nucleic acid amplification-based
tests lack the ability to discriminate between DNA from viable
and dead Mycobacterium tuberculosis (Mtb). Sputum smear and
microscopy lacks sensitivity (2–4) and the time-lag in receiving
Mtb sputum culture results limits their clinical application in
identifying those that are not responding to treatment. Critically,
all of these techniques require sputum samples, which are often
difficult to obtain from individuals after 2months of treatment (5,
6) at a time when there is the potential for modifying treatment
regimens. Additionally, sputum samples from individuals
with extra-pulmonary TB and/or HIV co-infection are often
paucibacillary (7–9).
Blood-based biomarkers have been proposed as an attractive
tool to diagnose, monitor and predict treatment response in
ATB. Blood (particularly fingerstick) can be taken from any
individual and biomarkers can be pooled to improve predictive
power and create one biosignature, resulting in the creation of
an inexpensive assay that could be used in the field by unskilled
personnel (5). This would also enable faster TB drug development
and personalized treatment regimens (5).
Previous studies have shown an ability to diagnose and
distinguish ATB and latent tuberculosis infection (LTBI) using
Mtb-specific CD4+ T-cell activation markers including; CD27,
IFN-γ, CD38, HLA-DR, and Ki67 (3, 10–17). Prior to treatment
initiation, high frequencies of activated Mtb-specific CD4+IFN-
γ
+ T-cells are seen in ATB patients compared to healthy
controls and LTBI participants after either ESAT-6/CFP-10
(EC) or purified protein derivative (PPD) stimulation (3, 10).
CD38 and HLA-DR expression on CD4+ cells declines rapidly
within the first month of treatment below the cut-off for
ATB, while CD27 and Ki67 expression declined more slowly
and this is correlated with mycobacterial load (3, 10). PPD-
specific CD4+CD27− T-cell frequencies have also been shown
to distinguish healthy BCG vaccinated individuals, LTBI and
ATB patients, suggesting exposure associated differentiation
(14, 18).
Whole blood cellular staining using a limited panel of
fluorescent parameters (CD3, HLA-DR, TNF-α, IFN-γ), using
a basic flow cytometer, demonstrated specificity at 100% and
sensitivity at 86% when distinguishing LTBI and ATB patients.
Thus implying feasibility for use in a resource-constrained
setting (11). CD4+Ki67+HLA-DR− T regulatory cells have also
demonstrated their potential use in predicting time to culture
conversion in multidrug resistant tuberculosis (MDR-TB) (19).
Receiver operating curve (ROC) analysis demonstrated that at
baseline, this T reg population could predict treatment response
with 81.2% sensitivity and 85% specificity (19).
The aim of this study was to determine the potential use of
activation markers expressed on both CD4+ and CD8+ T-cells
for monitoring ATB treatment response in a longitudinal cohort
of ATB adults fromWest Africa.
MATERIALS AND METHODS
Patients
We analyzed samples from 20 HIV-negative adult patients
prospectively recruited from the Medical Research Council at
The Gambia (MRCG) TB clinic with confirmed ATB (sputum
GeneXpert positive) following written informed consent. Patients
were recruited as part of the TB sequel project (20). Heparinized
blood samples were collected and processed at diagnosis
(baseline) and following 2 months of standard TB treatment. All
participants were mycobacteria growth indicator tube (MGIT)
sputum Mtb culture positive and drug sensitive at baseline.
Based on sputum culture positivity at 2 months participants
were grouped into either slow responders (culture positive at
2 months but negative by 6 months) or fast responders (culture
negative by 2 months).
Processing and Storage of Stimulated
Whole Blood
Five hundred microliter of whole blood was stimulated with
either ESAT-6/CFP-10 peptide pool [EC; overlapping 15mer
peptides reconstituted in 5% DMSO and H2O and topped up
to 1 mg/ml with PBS; final concentration 2.5 µg/ml/peptide;
Peptides & Elephants, Germany (Supplementary Table S1)],
PPD (10 µg/ml; Staten Serum Institute, Denmark) or phorbol
12-myristate 13-acetate (PMA; positive control; 10 µg/ml)
along with co-stimulatory antibodies (anti-CD28, anti-CD49d;
Becton Dickinson, United States) or unstimulated, cultured with
medium alone (negative control). Each tube was vortexed for 10 s
and 1 µl of 500× protein transport inhibitor was then added
(eBioscience, United Kingdom). Tubes were incubated overnight
at 37◦C, 5%CO2 with loose lids. After incubation, 50µl of 20mM
EDTA was added, vortexed and incubated for 15 min at room
temperature (RT). Cells were then lysed and fixed with 4.5 ml
of 1× FACS lysing solution (Becton Dickinson, United States)
and incubated for a further 9 min in the dark. Vials were then
centrifuged at 1500 rpm for 5 min, decanted and placed on ice.
One milliliter of cryosolution (20% DMSO, 80% FCS) was added
and cells were transferred into 1.8 ml cryovials and stored in
liquid nitrogen.
Sample Thawing
Patients’ samples from both groups (fast and slow responders)
and time points (baseline and 2 months) were processed
simultaneously, limiting batch to batch variation. Cryovials were
retrieved from liquid nitrogen, placed on dry ice and semi-
thawed in a 37◦C water bath. Samples were then transferred to a
Falcon tube (Becton Dickinson, United States) containing 10 ml
of PBS and mixed with a pasteur pipette. Tubes were centrifuged
at 1500 rpm for 5 min, supernatants discarded, and pellets
resuspended in 1 ml of 1× PBS. About 0.5 ml of the solution
was then transferred into 5 mm polystyrene tubes, centrifuged at
1500 rpm for 5 min and supernatants discarded carefully.
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Cell Surface Staining
Anti-CD3 BV786 (clone SP34-2), anti-CD4 BV605 (clone RPA-
T4), anti-CD27 APC (clone M-T271), anti-CD38 PE-CF594
(clone HIT2) (BD Biosciences, United Kingdom), and anti-HLA-
DR BV421 (clone L243) and anti-CD8a BV510 (clone RPA-T8)
(BioLegend, United Kingdom) antibodies were diluted in FACS
buffer (1% FBS, 0.1% EDTA, 0.05% sodium azide) to create a
surface staining cocktail. Titrations were conducted beforehand
to determine the optimal dilution for each antibody. Twenty
microliter of the cocktail was added per tube, vortexed, and
incubated for 30 min at RT in the dark. Cells were then washed
with 1 ml of FACS buffer, centrifuged at 1800 rpm for 5 min and
supernatants discarded.
Permeabilization and Intracellular
Cytokine Staining
Five hundred microliter of 1× BD FACSTM Permeabilizing
Solution 2 (Perm2) (BD Biosciences, United Kingdom) was
added to each tube at a 1:10 dilution, vortexed for 10 s and
tubes incubated for 20 min at RT in the dark. Cells were
then centrifuged at 1800 rpm for 5 min and supernatant was
carefully removed using a pipette. Twenty microliter of the
intracellular cytokine cocktail consisting of anti-Ki-67 PE (clone
Ki67) (BioLegend, United Kingdom), anti-IFN-γ AF700 (clone
B27) (BD Biosciences, United Kingdom), and anti-TNF-α Pe-
Cy7 (clone MAb11) (Invitrogen), diluted in Perm2 solution was
added per tube. Samples were incubated for 30 min at RT in
the dark, washed and resuspended in 300 µl of FACS buffer
prior to acquisition.
Flow Cytometry Acquisition
Flow-cytometry acquisition was performed using a LSR
Fortessa (BD Biosciences, United States). A minimum of
150,000 lymphocytes were acquired per tube. Positive and
negative ArCTM Amine Reactive Compensation Beads
(Life Technologies), BD CompBeads or UltraComp eBeads
(Invitrogen) were stained with a fluorochrome-conjugated
antibody to apply compensation. Data files were acquired with
FACSDivaTM software (BD Biosciences, United States), analyzed
using FlowJo software version 10.6 (Treestar, United States)
and tables were exported into Excel for statistical analysis.
Polyfunctional cells were analyzed using SPICE software (21).
Statistical Analysis
Statistical analysis was performed using GraphPad Prism 8.1.2
software (Software MacKiev, United States). For cytokine
responses, background was subtracted using the unstimulated
samples. Differences between paired baseline and 2-month
samples were analyzed using a Wilcoxon matched-paired rank
test. For analysis of fast and slow treatment responders,
a Kruskal–Wallis or Mann–Whitney U Test was used for
each time-point. Receiver operating characteristic (ROC) curve
analysis was conducted to determine the cut-offs with the
maximum sensitivity and specificity of statistically significant
markers to discriminate between fast and slow responders. A p
value less than 0.05 was considered to be statistically significant.
RESULTS
Patient Demographics
There was no significant difference in age between the fast and
slow responders, with a median[interquartile range (IQR)] of 25
[22–31] and 32 [28–35] years, respectively (Table 1). 80% were
male in both groups and all were HIV negative. Importantly the
GeneXpert cycle threshold (Ct) values did not significantly differ
between the groups (p = 0.23).
Flow Cytometry Gating Strategy
Lymphocytes were first gated based on forward and side scatter
(Supplementary Figure S1A). Doublets were then excluded
(Supplementary Figure S1B) and CD4+ and CD8+ T-cells
were gated (Supplementary Figure S1C). Within both CD4+
and CD8+ T-cell populations, CD27± subsets were gated
(Supplementary Figure S1D) followed by Boolean gating
analysis of activation markers (HLA-DR/CD38), Ki-67 and
cytokines (TNF-α, IFN-γ) (Supplementary Figure S1E). The
validity of the gates for the activation and functional markers
was established using fluorescence minus one control (data not
shown). This gating strategy was implemented due to the small
proportion of IFN-γ T cells observed. Total CD4+ and CD8+
T-cell populations did not change between time-points for any
of the stimulatory conditions (data not shown).
Changes in Cell Surface Activation
Marker Expression With Treatment
In the absence of stimulation, CD4+CD27− T-cells showed a
significant decrease in CD38 expression between baseline and
2 months of treatment (p = 0.0328; Figure 1B). The converse
was true for the CD4+CD27+ T-cells, with a significant increase
in CD38 expression over time (p = 0.0120; Figure 1E). No
difference in the expression of CD38 was seen on CD8+
T-cells (Figures 1H,K). There was also no significant change
in the proportion of CD27 (Figures 1A,D,G,J) and HLA-DR
expressing (Figures 1C,F,I,L) CD4+ and CD8+ T-cells between
the two time points.
Following EC stimulation, there was a significant increase in
HLA-DR expression both in CD4+CD27− and CD4+CD27+
T-cell compartments (p = 0.0328 and p = 0.0400, respectively;
Figures 2C,F). Within the CD4+CD27+ T-cell compartment
CD38 expression simultaneously increased over time (p = 0.0328;
TABLE 1 | Patient demographics.
Covariate Fast
responders
(n = 10)
Slow
responders
(n = 10)
P-value
Age (median [IQR]) 25 [22–31] 32 [28–35] 0.11
Male (%) 80 80
HIV positive (%) 0 0
GeneXpert Ct (median [IQR]) 17.8
[16.8–19.0]
16.8
[15.6–18.4]
0.23
HIV, human immunodeficiency virus; IQR, interquartile range; Ct, cycle theshold.
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FIGURE 1 | Activation marker expression in unstimulated samples. (A–C) CD4+CD27− total subset (A), CD38+ (B), and HLA-DR+ (C). (D–F) CD4+CD27+ total
subset (D), CD38+ (E), and HLA-DR+ (F). (G–I) CD8+CD27− total subset (G), CD38+ (H), HLA-DR+ (I). (J–L) CD8+CD27+ total subset (J), CD38+ (K), and
HLA-DR+ (L). Columns indicate median. Data were analyzed using Wilcoxon matched-pairs rank test.
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FIGURE 2 | Activation marker expression in ESAT-6/CFP-10 stimulated samples. (A–C) CD4+CD27− total subset (A), CD38+ (B), and HLA-DR+ (C). (D–F)
CD4+CD27+ total subset (D), CD38+ (E), and HLA-DR+ (F). (G–I) CD8+CD27− total subset (G), CD38+ (H), and HLA-DR+ (I). (J–L) CD8+CD27+ total subset
(J), CD38+ (K), and HLA-DR+ (L). Columns indicate median. Data were analyzed using Wilcoxon matched-pairs rank test.
Frontiers in Immunology | www.frontiersin.org 5 September 2020 | Volume 11 | Article 572620
Vickers et al. TB Treatment Response Markers
Figure 2E), but no difference in CD38 expression within the
CD4+CD27− (Figure 2B) or in but no difference in CD27
expression in either compartment was seen (Figures 2A,D,G,J).
No differences in CD38 and HLA-DR expression were
seen within the CD8+CD27− and CD8+CD27+ subsets
(Figures 2H,I,K,L). No significant differences in levels of CD27,
HLA-DR and CD38 expression on CD4+ and CD8+ CD27
expressing T-cell subsets were seen over time following PPD and
PMA stimulation (Supplementary Figures S2, S3).
Changes in Cytokine and Proliferation
Markers With Treatment
In the absence of stimulation there was no difference in IFN-
γ
+ (Figure 3A) but a significant decrease at 2 months in the
proportion of TNF-α+ (p = 0.0172; Figure 3B) and Ki-67+
(p = 0.0400; Figure 3C) producing cells within the CD4+CD27−
and CD4+CD27+TNF-α+ T-cell subpopulations (p = 0.0204;
Figure 3E). No difference in IFN-γ or Ki-67 expression was
seen within the CD4+CD27+ subset (Figures 3D,F). Within
the CD8+CD27− subset, there was a significant decline in the
proportion of IFN-γ+ and Ki-67+ producing cells (p = 0.0494
and p = 0.0007, respectively) but not TNF-α+ producing cells
(Figures 3G–I). Within the CD8+CD27+ subset there was also
a significant decrease in the proportion of IFN-γ+ producing
cells (p = 0.0225) but not TNF-α+ or Ki-67+ producing cells
(Figures 3J–L).
Following EC stimulation, the CD4+CD27− subset showed
a significant decrease in IFN-γ+ expressing cells and a
significant increase in Ki67+ producing cells (p = 0.0351 and
p = 0.0400, respectively; Figures 4A–C). No significant changes in
intracellularmarker expression was seen within the CD4+CD27+
compartment (Figures 4D–F). Within the CD8+CD27− subset,
a significant decrease in IFN-γ (p = 0.0019; Figure 4G) and TNF-
α (p = 0.0034; Figure 4H) production over time was seen, with
no significant variation in intracellular marker expression in the
CD8+CD27+ T-cell compartment (Figures 4J–L).
No significant differences were seen following PPD
stimulation (Supplementary Figure S4) but a significant
increase in IFN-γ and TNF-α production was seen following
PMA stimulation at 2 months compared to baseline for all T-cell
subsets described (Figure 5). Conversely, Ki-67 expression in the
CD8+CD27− T cell compartment decreased significantly from
baseline to 2 months (p = 0.0056, Figure 5L).
Comparison of Slow Versus Fast
Treatment Responders
The majority of significant differences seen were in the kinetics
of change over time within the groups. Slow responders showed
a significant increase in both CD38 and HLA-DR expression
from baseline to 2 months in the unstimulated cells within
the CD4+CD27+ T cell population, that was not seen in the
fast responder group (p = 0.0273 and p = 0.0371, respectively;
Figures 6A,B). The proportion of CD4+CD27+HLA-DR+ cells
also increased only in the slow responder group by 2 months
after both PPD (p = 0.0273) and EC stimulation (p = 0.0273);
Figures 6C,D). Levels of PPD-stimulated CD4+CD27−IFN-γ+
cells significantly increased at 2 months compared to baseline,
in only the fast responders (p = 0.0020; Figure 6E). Following
EC stimulation there was a significantly lower proportion
of CD8+CD27−IFN-γ+ and CD8+CD27+TNF-α+ cells at
2months compared to baseline in the slow responders (p = 0.0096
and p = 0.0137, respectively; Figures 6F,G).
In unstimulated, EC and PMA conditions, no difference
between treatment response groups were seen at baseline or
2 months (data not shown). Nonetheless, two discriminatory
subsets were found following PPD stimulation; levels of
CD4+CD27+HLA-DR+CD38+ and CD8+CD27−IFN-γ+ T cell
populations were significantly higher in the slow responder group
compared to the fast responder group at baseline (p = 0.0077
and p = 0.0105, respectively; Figures 6H,I). When ROC analysis
was performed, baseline frequencies of CD8+CD27−IFN-γ+ and
CD4+CD27+HLA-DR+CD38+ T cells could predict treatment
response with a 80% sensitivity and 70 and 100% specificity,
respectively (AUC of 0.82, p = 0.0156 and 0.84, p = 0.0102)
(Figures 6J,K).
Polyfunctional T-Cell Changes With TB
Treatment
We also analyzed qualitative responses before and at 2 months
of TB treatment using SPICE analysis of activation and cytokine
marker combinations within each subset (Figure 7). Following
PMA stimulation, there were no differences in any subset
between baseline and 2 months with the majority of cells positive
for TNF-α, IFN-γ, and/or Ki-67 but not HLA-DR nor CD38
(purple/pink categories). Following EC stimulation, diverse cell
populations were present with the predominant population
positive for all markers except CD38 (population 17). The overall
polyfunctionality was not significantly different between fast
and slow responders but slow responders showed a significantly
different qualitative profile in response to EC stimulation at
2 months compared to baseline in the CD8+CD27+ subset,
which was not seen in the fast responders (p = 0.0231; Figure 7D).
At baseline, the predominant subset expressed TNF-α only
(subset 31) whereas at 2 months, the predominant subset were
cells producing TNF-α and IFN-γ together with Ki-67 but with
the absence of CD38 and HLA-DR (population 25).
DISCUSSION
This study looked at the use of activation and functional markers
for monitoring and predicting treatment responses. Overall,
activation marker expression (particularly CD38) decreased in
the CD4+CD27− subset but increased in the CD4+CD27+ subset
by 2 months of therapy compared to baseline. In addition,
cytokine responses to EC stimulation were significantly reduced,
but increased following PMA stimulation. This is consistent
with our previous unpublished findings demonstrating a general
reduction in overall immune responsiveness in T-cells from active
TB patients, which is restored post treatment. When patients
were analyzed based on response to therapy, slow responders
had significantly more PPD-specific CD8+CD27−IFN-γ+ and
CD4+CD27+HLA-DR+CD38+ T-cells than fast responders
at baseline. Receiver operating characteristics curve analyses
showed that baseline PPD-stimulated CD8+CD27−IFN-γ+ and
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FIGURE 3 | Intracellular cytokine and proliferation marker expression in unstimulated samples. (A–C) CD4+CD27− IFN-γ+ (A), TNF-α+ (B), and Ki-67+ (C). (D–F)
CD4+CD27+ IFN-γ+ (D), TNF-α+ (E), and Ki-67+ (F). (G–I) CD8+CD27− IFN-γ+ (G), TNF-α+ (H), Ki-67+ (I). (J–L) CD8+CD27+ IFN-γ+ (J), TNF-α+ (K), and
Ki-67+ (L). Columns indicate median. Data were analyzed using Wilcoxon matched-pairs rank test.
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FIGURE 4 | Intracellular cytokine and proliferation marker expression in EC stimulated samples. (A–C) CD4+CD27− IFN-γ+ (A), TNF-α+ (B), and Ki-67+ (C). (D–F)
CD4+CD27+ IFN-γ+ (D), TNF-α+ (E), and Ki-67+ (F). (G–I) CD8+CD27− IFN-γ+ (G), TNF-α+ (H), and Ki-67+ (I). (J–L) CD8+CD27+ IFN-γ+ (J), TNF-α+ (K), and
Ki-67+ (L). Columns indicate median. Data were analyzed using Wilcoxon matched-pairs rank test.
CD4+CD27+HLA-DR+CD38+ T cells could predict treatment
response with 80% sensitivity and specificity of 70 and
100%, respectively.
Our aim was to see if blood-based biomarkers could be used at
2 months rather than sputum culture as an indication of response
to therapy and at baseline as prognostic markers for response to
therapy. Previous studies have gated on IFN-γ+ T cells (both
CD4+ and CD8+) prior to activation marker analysis (3, 10,
11). However, this was not possible in our study due to the low
level of IFN-γ+ cells following both EC and PPD stimulation.
This reduced responsiveness has often been observed between
East and West Africans (unpublished data) and highlights the
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FIGURE 5 | Intracellular cytokine and proliferation marker expression in PMA stimulated samples. (A–C) CD4+CD27− IFN-γ+ (A), TNF-α+ (B), and Ki-67+ (C).
(D–F) CD4+CD27+ IFN-γ+ (D), TNF-α+ (E), and Ki-67+ (F). (G–I) CD8+CD27− IFN-γ+ (G), TNF-α+ (H), and Ki-67+ (I). (J–L) CD8+CD27+ IFN-γ+ (J), TNF-α+
(K), and Ki-67+ (L). Columns indicate median. Data were analyzed using Wilcoxon matched-pairs rank test.
requirements for identification of global biomarkers, validated
in multiple contexts. Nonetheless, our results suggest gating on
IFN-γ+ T cells is not strictly necessary and may be limited by low
relevant cell counts.
CD27 acts as a T-cell differentiation marker; expression is
gradually lost as the T-cell transitions from naïve or memory
to effector and differentiation state is dictated by strength and
duration of antigen stimulation (22). Consequently, CD27 is
expressed on central memory (CM) T-cells, variably expressed on
effector memory (EM) T-cells and is not expressed on terminal
effector memory (TEMRA) T-cells (22–25). As we expected,
the CD4+CD27− T-cell subset was the predominantly activated
population for all stimulation conditions, as demonstrated
through HLA-DR, CD38, IFN-γ, and TNF-α expression levels,
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FIGURE 6 | Analysis of slow versus fast treatment responders. (A–G) Activation and cytokine marker analysis with different stimulation conditions (indicated). The
majority of differences were seen were within groups. (H) CD4+CD27+HLA-DR+CD38+ cells at baseline between fast and slow responders. (I) CD8+CD27− IFN-γ+
cells at baseline between fast and slow responders. (J) ROC curve of CD8+CD27− IFN-γ+ cells at baseline. (K) ROC curve of CD4+CD27+CD38+HLA-DR+ cells at
baseline. Columns indicate median. Data were analyzed using Kruskal–Wallis or Wilcoxon matched-pairs rank test (A–G).
which is consistent with previous studies (18, 21). CD4+ T-cells
are important in controlling Mtb infection and those that are
CD27− are mostly TEMRA, EM, and effector cells which exert
the quickest and strongest activated effector response (18, 26).
However, this subset is also the most likely to undergo activation
induced cell death and to be exhausted from persistent antigen
stimulation in vivo which will reduce their frequency (27).
Overall, a general decrease in cytokine expression in
unstimulated samples from baseline to 2 months was witnessed
alongside general cell responsiveness to PMA. These results
suggest that rather than general T-cell anergy, persistent
MTB-antigen stimulation (in vitro and in vivo) in these
ATB patients has led to dysfunction of these antigen-specific
T-cells, resulting in apoptosis and exhaustion (27). Earlier
studies have revealed that persistent antigen stimulation
in ATB results in an upregulation of inhibitory receptors
such as programmed cell death protein 1 (PD-1), resulting
in the inhibition and exhaustion of MTB-specific CD4+ T
cell (27–29). Therefore, alongside terminally differentiated
T-cells, these exhausted populations demonstrate much
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FIGURE 7 | SPICE analysis. Combinatorial analysis of activation, cytokine and proliferation markers was performed at baseline and 2 months of therapy. Pie graphs
illustrate differences in each category for each subset. (A) CD4+CD27−; (B) CD4+CD27+; (C) CD8+CD27−; (D) CD8+CD27+.
lower levels of cytokine production compared to effector T
cells (22).
When analyzing changes from baseline to 2 months our
findings were mostly consistent with previous studies (3,
10, 30). Elevated levels of IFN-γ, TNF-α, CD38, and Ki67
decreased in the CD4+CD27− population from baseline to
2 months, likely due to a diminishing bacterial burden (3).
However, a significant increase in HLA-DR expression in
the CD4+CD27− subset after 2 months of treatment was
not anticipated. A potential explanation for this phenomenon
is a reduction in T regulatory cells (Tregs) (19, 31, 32).
Nevertheless, these results reveal that whole blood samples from
ATB patients may not require in vitro Mtb-specific stimulation
to deliver valuable information. The significant decrease in
activation marker expression within the CD4+CD27− T cell
population from baseline to 2 months suggests the potential
ability to monitor treatment adherence using unstimulated whole
blood. Additionally, measuring activation at baseline may prove
beneficial as a point-of-care diagnostic tool.
When participants were stratified based on treatment
response, the majority of the changes from baseline to 2 months
occurred within the slow responder group in the absence of
in vitro stimulation. These included an increase in expression
of CD38 and HLA-DR expression on the CD4+CD27+ subset.
Interestingly, specific CD4+ and CD8+ T-cell subsets were able
to predict treatment response at baseline: slow responders had
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significantly more CD8+CD27− T cells producing IFN-γ than
fast responders with PPD stimulation at baseline. CD8+ T
cells have been shown to play a role in MTB immunity in
more severe disease (33) but CD8+CD27− T cells producing
IFN-γ and TNF-α are also associated with protection in Mtb
infection (33). However, this implies a difference in disease
severity/inflammation between treatment response groups which
is not supported by our findings. Nonetheless, this suggests that
if an individual is diagnosed with ATB and is showing high
production levels of IFN-γ by the CD8+CD27− subset, they may
be at greater risk of still being culture positive at 2 months and
thus the CD8+CD27-IFN-γ+ subset could be used as a predictive
marker. This could be used in conjunction with CD4+CD27+
T cells, co-expressing CD38 and HLA-DR to improve positive
predictive value.
There are several limitations of this study, mainly due to small
sample size making it difficult to adjust for possible confounders
such as BMI, alcohol abuse, diabetes mellitus, and delay in
presentation. Another possible explanation for the difference in
treatment response could be a higher bacterial burden at baseline,
however, there was no difference in GeneXpert Ct between the
groups suggesting that a slow response was not simply due to
higher bacterial load at baseline. Future work should corroborate
these findings in a larger cohort of ATB patients using fresh
cells to progress toward real-time monitoring and application
in the field. Analysis of Treg cells from other T cell subsets
would also be important together with addition of an exhaustion
marker such as PD-1 to help prove our hypothesis on T cell
exhaustion in patients at baseline (34). It would also be of interest
to analyze a post-treatment time-point to determine the stability
of our findings.
In summary, our pilot data suggest there is potential for use
of activation and cytokine markers for predicting andmonitoring
treatment response in HIV negative ATB patients in The Gambia.
However, this requires validation in a larger cohort. Analysis of
baseline levels of IFN-γ production from the CD8+CD27− subset
and HLA-DR and CD38 co-expression in the CD4+CD27+
subset after PPD stimulation has the potential to predict response
to treatment at 2 months. Further, our results demonstrate
the ability of analyzing unstimulated samples for diagnosis and
monitoring treatment adherence – warranting further evaluation
for the development of a point of care test.
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